title: [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
abstract: Following various articles in literature which have appeared in the last 3 years regarding the neurotoxicity of desferrioxamine B we studied, from the auditory functionality point of view, 95 patients affected with transfusion-dependent thalassemic syndromes, under regular chelation treatment with desferrioxamine B. Our results lead us to conclude that at standard doses, between 40 and 60 mg/Kg/day, desferrioxamine B does not demonstrate a neurotoxicity enough to cause an organic deficit in the auditory sphere, while maintaining therapeutic efficacy.
authors.affiliation: II Clinica Otorinolaringoiatrica, Università di Milano, Italia.
authors.forename: R M
authors.initials: RM
authors.lastname: Gaini
authors.forename: E
authors.initials: E
authors.lastname: Moretti
authors.forename: C
authors.initials: C
authors.lastname: Boffa
authors.forename: S
authors.initials: S
authors.lastname: Terzoli
authors.forename: V
authors.initials: V
authors.lastname: Carnelli
mesh_terms: D000158:Acoustic Impedance Tests; D000293:Adolescent; D000328:Adult; D001299:Audiometry; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D013789:Thalassemia / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D003676:Deferoxamine
vernacular_title: Valutazione audiologica in pazienti affetti da sindromi talassemiche trattati con desferossamina B.